Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05035641 · ClinicalTrials.gov registry record · Phase 2
A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
A Phase 2 study of Renal Anemia, sponsored by Kind Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
- 8
- Study locations
NCT05035641: Completed Phase 2 study of Renal Anemia, sponsored by Kind Pharmaceuticals.
NCT05035641 is a Phase 2 study of Renal Anemia that has completed, run by Kind Pharmaceuticals. The registered enrollment target is 113 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05035641, a Phase 2 study of Renal Anemia, has completed, sponsored by Kind Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a pilot phase II study to evaluate the safety and efficacy of AND017 in NDD-CKD patients
Primary Outcome
Incidence of adverse events
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AND017
Study Locations (8)
California
- Amicis Research Center - Northridge
Florida
- Clinical Site Partners - Winter Park
Louisiana
- Northwest Louisiana Nephrology - Shreveport
Michigan
- Elite Research Center - Flint
North Carolina
- Metrolina Nephrology Associates - Charlotte
Tennessee
- Southeast Renal Research Institute - Chattanooga
Texas
- Clinical Advancement Center, PLLC - San Antonio
Beijing Municipality
- Peking University People's Hospital - Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2021-10-18 |
| Est. Completion | 2023-07-24 |
| Phase | Phase 2 |
What the finished NCT05035641 record still lists
NCT05035641 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Renal Anemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05035641 lists 8 locations in 8 states (California, Florida, Louisiana).
Frequently Asked Questions
What is clinical trial NCT05035641 about?
NCT05035641 is a clinical study titled "A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients". This is a pilot phase II study to evaluate the safety and efficacy of AND017 in NDD-CKD patients
What is the current status of trial NCT05035641?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2021-10-18. Estimated completion is 2023-07-24.
What conditions does trial NCT05035641 study?
This clinical trial studies the following conditions: Renal Anemia.
What interventions are being tested in trial NCT05035641?
The interventions under investigation include: Placebo (DRUG), AND017 (DRUG).
Who is sponsoring clinical trial NCT05035641?
This trial is sponsored by Kind Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05035641 being conducted?
This trial has 8 study locations across California, Florida, Louisiana, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05035641's enrollment target sits among peer trials
113 631st of 2000 higher than 1,370 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
COMPLETED · Phase 4
-
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI